Fact Meets Function

Improving Cognition in Bipolar Disorder: A Systematic Review of Current Pharmacological and Nutraceutical Approaches.

This systematic review examined pharmacological and nutraceutical interventions aimed at improving cognitive impairment in bipolar disorder patients. The review synthesized evidence on various treatment approaches, including methylene blue among other compounds, to identify current strategies for addressing cognitive dysfunction in this population. Evidence level: Review of human clinical and related studies.

Improving Cognition in Bipolar Disorder: A Systematic Review of Current Pharmacological and Nutraceutical Approaches. Read Post »

Pretreatment With Methylene Blue Atenuates Seizures, Cognitive Impairment, Hippocampal Neuronal Damage and Oxidative Stress in Pentylenetetrazole-Kindled Rats.

This animal model study investigated whether pretreatment with methylene blue could reduce seizures and associated brain damage in rats subjected to repeated seizure induction via pentylenetetrazole. Researchers found that methylene blue pretreatment attenuated seizure severity, prevented cognitive impairment, reduced hippocampal neuronal damage, and decreased oxidative stress markers compared to untreated seizure-prone rats. This is an animal model study with potential translational relevance, though findings require further investigation in human clinical populations before any clinical applications can be considered.

Pretreatment With Methylene Blue Atenuates Seizures, Cognitive Impairment, Hippocampal Neuronal Damage and Oxidative Stress in Pentylenetetrazole-Kindled Rats. Read Post »

Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease.

This Phase 3 clinical trial tested a methylene blue derivative called HMTM in patients with mild cognitive impairment and early Alzheimer’s disease. The compound works by targeting tau protein tangles in the brain, which are a hallmark of Alzheimer’s. The study measured clinical outcomes, brain imaging changes, and blood markers to assess whether the treatment could slow cognitive decline or improve symptoms.

Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease. Read Post »

A 10-year retrospective study of patients with acquired methemoglobinemia: causative agents, clinical characteristics, and outcomes.

This study looked at patients who developed methemoglobinemia, a serious blood condition where oxygen transport is impaired, after exposure to certain chemicals and drugs over 10 years in Thailand. The research focused on identifying what caused the condition, how patients presented clinically, and what happened to them. This was a safety study examining harmful effects rather than therapeutic benefits of methylene blue.

A 10-year retrospective study of patients with acquired methemoglobinemia: causative agents, clinical characteristics, and outcomes. Read Post »

Methylene Blue-Enriched Feed Mitigates Acute Nitrite Intoxication in Nile tilapia (Oreochromis niloticus).

This study tested whether methylene blue added to fish feed could protect tilapia from nitrite poisoning, which causes dangerous oxygen transport problems. Fish fed methylene blue for 5 days before nitrite exposure had no deaths and better blood oxygen levels compared to control fish that experienced deaths and organ damage. The methylene blue worked by preventing the conversion of healthy hemoglobin to dysfunctional methemoglobin. This suggests oral methylene blue could be an effective way to protect against oxygen transport disruption.

Methylene Blue-Enriched Feed Mitigates Acute Nitrite Intoxication in Nile tilapia (Oreochromis niloticus). Read Post »

Atypical population pharmacokinetics of hydromethylthionine in patients with Alzheimer’s disease explains unexpected phase 3 trial results.

This study examined how methylene blue (hydromethylthionine) is processed in the body when given orally to Alzheimer’s patients versus healthy people. The researchers found that Alzheimer’s patients process the drug differently than expected, which helps explain why previous clinical trials had unexpected results. The drug targets tau protein clumps in the brain that contribute to Alzheimer’s disease and also has other brain benefits.

Atypical population pharmacokinetics of hydromethylthionine in patients with Alzheimer’s disease explains unexpected phase 3 trial results. Read Post »

Persistent methaemoglobinaemia due to unsupervised use of topical dapsone-adapalene.

This case report documents a patient who developed persistent methemoglobinemia from unsupervised use of a topical dapsone-adapalene combination product, highlighting the risk of systemic absorption and adverse effects from unmonitored application of this dermatological agent. The patient’s methemoglobinemia was treated with methylene blue, demonstrating its effectiveness in reversing dapsone-induced oxidative damage to hemoglobin. This is a human clinical case report (low evidence level) that illustrates an important safety concern with topical dapsone use.

Persistent methaemoglobinaemia due to unsupervised use of topical dapsone-adapalene. Read Post »

Effect of intraoperative methylene blue on postoperative delirium in elderly patients undergoing joint replacement: a randomized controlled trial.

This randomized controlled trial investigated whether intraoperative methylene blue administration reduces postoperative delirium in elderly patients undergoing joint replacement surgery. The study found that methylene blue treatment was associated with a lower incidence of postoperative delirium compared to control, with specific reductions in both the rate and severity of delirium during the postoperative period. This evidence is from a human clinical trial, representing a higher level of evidence for clinical outcomes.

Effect of intraoperative methylene blue on postoperative delirium in elderly patients undergoing joint replacement: a randomized controlled trial. Read Post »

Development and evaluation of a novel prehospital antidote service providing methylthioninium chloride (methylene blue) for sodium nitrite poisoning.

This study describes how emergency medical services developed a treatment protocol using methylene blue as an antidote for sodium nitrite poisoning. Sodium nitrite poisoning causes dangerous levels of methemoglobin in the blood, which prevents proper oxygen transport. Methylene blue was used by specialized paramedic teams to reverse this life-threatening condition. This represents a specific emergency medical application rather than a general health supplement use.

Development and evaluation of a novel prehospital antidote service providing methylthioninium chloride (methylene blue) for sodium nitrite poisoning. Read Post »

Food additives for the central nervous system, useful or harmful? An evidence-based review.

This review article examined the effects of various food additives on central nervous system function by synthesizing existing evidence on their potential benefits and harms. The authors found that while some additives (such as methylene blue) demonstrated neuroprotective properties in research settings, many commonly used additives lack sufficient human clinical evidence, with most supporting data coming from animal models and in vitro studies rather than human trials. The evidence level is a **review of human clinical, animal model, and in vitro studies**.

Food additives for the central nervous system, useful or harmful? An evidence-based review. Read Post »

Methylene Blue Protects Spatial Working Memory after Traumatic Brain Injury in Mice by Affecting Mitochondrial Quality Control System.

This animal model study investigated how methylene blue affects spatial working memory recovery in mice following traumatic brain injury, finding that the compound protected memory function by modulating the mitochondrial quality control system (including autophagy and mitophagy pathways). Researchers observed that methylene blue treatment improved performance on spatial working memory tasks and influenced key markers of mitochondrial homeostasis in brain tissue after injury. The evidence is from an animal model (mouse) study and does not establish effects in human patients.

Methylene Blue Protects Spatial Working Memory after Traumatic Brain Injury in Mice by Affecting Mitochondrial Quality Control System. Read Post »

Intranasal methylene blue administration confers neuroprotection in rats subjected to exhaustive exercise training.

This animal model study investigated whether intranasal methylene blue administration could protect against neurological damage in rats subjected to exhaustive exercise training. Researchers found that methylene blue treatment conferred neuroprotective effects in the studied rats, suggesting potential mechanisms for mitigating exercise-induced neural stress. This evidence is from an animal model and would require further human clinical investigation before application to human populations.

Intranasal methylene blue administration confers neuroprotection in rats subjected to exhaustive exercise training. Read Post »

Scroll to Top